Pain Treatments

King’s commitment to responsible pain management begins with innovative medicines that provide effective relief of acute and chronic pain.

News Regarding Pain Treatments in Development

8/27/2008	Pain Therapeutics and King Pharmaceuticals Develop a New Abuse-Resistant Prescription Pain Medication
8/19/2008	Pain Therapeutics and King Pharmaceuticals Announce Final Data of Remoxy Phase III Study at World Pain Congress in Scotland
8/12/2008	FDA Accepts Remoxy® New Drug Application and Grants Priority Review
6/17/2008	Acurox™ Tablets Meet Primary Endpoint In Pivotal Phase III Study
6/10/2008	Pain Therapeutics and King Pharmaceuticals Announce Submission Of New Drug Application for Remoxy™
5/27/2008	King Pharmaceuticals Exercises Option to License Third Opioid Product Utilizing Acura's AVERSION® Technology

Available Treatments

AVINZA^® (morphine sulfate extended-release capsules) is approved for the once-daily treatment of moderate to severe chronic pain in patients who require continuous, around-the-clock opioid therapy for an extended period of time.

Click here for Important Safety Information

SKELAXIN^® 800mg (metaxalone) Tablets is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.

Click here for Important Safety Information

King's Approach

Pain is a serious and complex medical condition that affects more than one quarter of adult Americans. At King Pharmaceuticals,^® Inc., we believe responsible pain management is achieved through a balance between pain control and minimizing the risks of misuse and abuse.

King is committed to providing resources and medicines to patients and their treatment teams to achieve optimal pain control. As we bring new medicines to market, we are focused on innovative acute and chronic pain treatments that use new technologies to help minimize potential risks of unintended use.

Other Pain Related News

9/11/2008	King to Commence Cash Tender Offer for Alpharma at $37 Per Share
8/22/2008	King Pharmaceuticals Provides Updated Replay Information for Conference Call Regarding Proposed Acquisition of Alpharma
8/22/2008	King Proposes Acquisition of Alpharma for $33 Per Share in Cash